NCCN 2020 Nursing Program: A Practical Approach to the Diagnosis and Treatment of Anemia in Cancer Patients

May 14, 2020

The decision regarding the best treatment option for cancer patients with anemia is dependent on many factors including the presence of symptoms, etiology of anemia, chemotherapy treatment intent and patient comorbidities. While red blood cell (RBC) transfusion is best for symptomatic patients requiring an immediate boost in hemoglobin levels, consideration of erythropoiesis-stimulating agent (ESA) therapy and/or iron supplementation may be warranted for the long-term management of anemia in high-risk patients or in asymptomatic patients with comorbidities. The risks and goals associated with each treatment modality should always be discussed with the patient prior to treatment. Therefore, increased education and awareness of these risks and goals will help minimize post-transplant complications, maximize patient communication and ensure the delivery of optimal care.

Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the diagnostic approach for determining the etiology of anemia
  • Identify appropriate therapeutic interventions based on the etiology of anemia
  • Provide examples of the advantages and disadvantages of RBC transfusion, oral iron, and IV iron therapy
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Taiho Oncology, Inc.

This activity is supported by independent medical education grants from:

  • Bristol-Myers Squibb
  • Celgene Corporation

This activity is supported by independent educational grants from:

  • AbbVie
  • Incyte
  • Merck & Co., Inc.
Course summary
Available credit: 
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
04/27/2020
Course expires: 
08/14/2020
Event starts: 
05/14/2020 - 11:00am EDT
Event ends: 
05/14/2020 - 12:00pm EDT
Cost:
$0.00
Part of: 
NCCN 2020 Nursing Program: Advancing Oncology Nursing™
Add to calendar: 

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
UCSF Helen Diller Family Comprehensive Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Daiichi- Sankyo Co.: Honoraria
Merck & Co., Inc. : Honoraria
Salix Pharmaceuticals: Consulting Fee

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Lenora Pluchino, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Available Credit

  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Thursday, May 14, 2020, from 11:00 AM - 12:00 PM EDT (UTC -4).

Required Hardware/software

To complete this activity, users will need: